CAN YOU IDENTIFY these medications for neurologic disorders? To find out, match each brand name in Section I with its generic name in Section II.

Section I

______ 1. Xcopri (SK Life Science, Inc.)

______ 2. Mayzent (Novartis Pharmaceuticals Corp.)

______ 3. Ubrelvy (Allergan USA, Inc.)

Section II

a. siponimod. Classified as a sphingosine 1-phosphate receptor modulator, this drug is used to treat relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapse-remitting disease, and active secondary progressive disease. Dosing is based on CYP2C9 genotype. Six-hour monitoring after the first dose is recommended for patients with a history of cardiac disorders due to the risk of bradydysrhythmias. Teach patients to take the tablets whole.

b. cenobamate. This orally administered antiepileptic drug is prescribed to treat partial-onset seizures in adults. Teach patients to adhere strictly to the prescribed dosage regimen, titration schedule, and dosage adjustments to minimize the risk of serious adverse reactions, including increased seizure activity if the drug is discontinued abruptly. This drug is a federally controlled substance. Teach patients to keep it in a safe place to prevent misuse and abuse.

c. ubrogepant. This calcitonin gene-related peptide receptor antagonist is administered orally as a single dose to treat acute migraine with or without aura in adults. If needed, a second dose may be administered at least 2 hours after the initial dose. The most common adverse reactions are nausea and somnolence. Teach patients to write down when they have headaches and when they take the drug so they can talk to their healthcare provider about how it is working for them.

Answers: 1b, 2a, 3c